Join to view full profile
830 Pavasiya CircleIvins, UT 84738
Phone+1 951-296-7867
Dr. Wedel is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins University School of MedicineClass of 1972
Certifications & Licensure
CA State Medical License 1987 - 2018
Clinical Trials
- Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea Start of enrollment: 2006 May 01
- Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment Start of enrollment: 2003 Feb 01
- Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715 Start of enrollment: 2006 Aug 01
Publications & Presentations
PubMed
- 20 citationsAntisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteinsJeremy D. Furtado, M. K. Wedel, Frank M. Sacks
Journal of Lipid Research. 2012-04-01 - 94 citationsEfficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia.Fatima Akdim, Diane Tribble, JoAnn Flaim, Rosie Z. Yu, John Su
European Heart Journal. 2011-05-18 - 119 citationsEfficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin TherapyFatima Akdim, Erik S.G. Stroes, Eric J.G. Sijbrands, Diane Tribble, Mieke D. Trip
Journal of the American College of Cardiology. 2010-04-13
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
